ArticleJournal of neuroimmunology2013
Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis.
Article in Journal of neuroimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Targeting the Dectin-1 Receptor in Neuroinflammation: Therapeutic Implications for Neuropsychiatric Disorders.ACS chemical neuroscience · 2025Review
- Emerging roles of Dectin-1 in noninfectious settings and in the CNS.Trends in immunology · 2021Review
- Article
- Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop.Scientific reports · 2020Article
- Zymosan by-passes the requirement for pulmonary antigen encounter in lung tissue-resident memory CD8Mucosal immunology · 2019Article
- Pattern Recognition Receptors in Multiple Sclerosis and Its Animal Models.Frontiers in immunology · 2019Review
- Protective effects of zymosan on heat stress-induced immunosuppression and apoptosis in dairy cows and peripheral blood mononuclear cells.Cell stress & chaperones · 2018Article
- The hygiene hypothesis in autoimmunity: the role of pathogens and commensals.Nature reviews. Immunology · 2018Review
- Article
- c-kit plays a critical role in induction of intravenous tolerance in experimental autoimmune encephalomyelitis.Immunologic research · 2015Article
- Article
- TLR2-dependent activation of β-catenin pathway in dendritic cells induces regulatory responses and attenuates autoimmune inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Fungal β-glucan, a Dectin-1 ligand, promotes protection from type 1 diabetes by inducing regulatory innate immune response.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Diagnostic potential of antibody titres against Candida cell wall β-glucan in Kawasaki disease.Clinical and experimental immunology · 2014Article
- T cell activation status determines the cytokine pattern induced by zymosan and bacterial DNA both in thymocytes and splenocytes.Clinical and experimental immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Zymosan has previously been reported to have both pro-inflammatory and anti-inflammatory effects. Here we demonstrate that low dose zymosan prevented or reversed chronic and relapsing paralysis in EAE. In suppressing CNS autoimmune inflammation, zymosan not only regulated APC costimulator and MHC class II expression, but also promoted differentiation of regulatory T cells. Following adoptive transfer of zymosan-primed CD4(+) T cells, recipient mice were protected from EAE. In contrast, a MAPK inhibitor and a blocker of β-glucan, reversed the effects of zymosan. These results demonstrate that zymosan may be a promising beneficial agent for Multiple Sclerosis (MS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.